Alpha-linolenic acid supplementation and resistance training in older adults.
Increased inflammation with aging has been linked to sarcopenia. The purpose of this study was to evaluate the effects of supplementing older adults with alpha-linolenic acid (ALA) during a resistance training program, based on the hypothesis that ALA decreases the plasma concentration of the inflammatory cytokine tumor necrosis factor (TNF)-alpha and interleukin (IL)-6, which in turn would improve muscle size and strength. Fifty-one older adults (65.4 +/- 0.8 years) were randomized to receive ALA in flax oil (~14 g.day-1) or placebo for 12 weeks while completing a resistance training program (3 days a week). Subjects were evaluated at baseline and after 12 weeks for muscle thickness of knee and elbow flexors and extensors (B-mode ultrasound), muscle strength (1 repetition maximum), body composition (dual energy X-ray absorptiometry), and concentrations of TNF-alpha and IL-6. Males supplementing with ALA decreased IL-6 concentration over the 12 weeks (62 +/- 36% decrease; p = 0.003), with no other changes in inflammatory cytokines. Chest and leg press strength, lean tissue mass, muscle thickness, hip bone mineral content and density, and total bone mineral content significantly increased, and percent fat and total body mass decreased with training (p < 0.05), with the only benefit of ALA being a significantly greater increase in knee flexor muscle thickness in males (p < 0.05). Total-body bone mineral density improved in the placebo group, with no change in the ALA group (p = 0.05). ALA supplementation lowers the IL-6 concentration in older men but not women, but had minimal effect on muscle mass and strength during resistance training.
Cornish
Stephen M
SM
Nutrition Research Division, Health Canada, 251 Sir Frederick Banting Driveway, Ottawa, ON K1A0K9, Canada. stephen_cornish@hc-sc.gc.ca
Chilibeck
Philip D
PD
D000367:Age Factors; D000368:Aged; D000375:Aging; D015519:Bone Density / Q000187:drug effects; D019587:Dietary Supplements; D004311:Double-Blind Method; D002149:Energy Intake; D005260:Female; D006801:Humans; D007249:Inflammation / Q000276:immunology / Q000503:physiopathology / Q000517:prevention & control*; D018836:Inflammation Mediators / Q000097:blood; D015850:Interleukin-6 / Q000097:blood; D008297:Male; D008875:Middle Aged; D053580:Muscle Strength / Q000187:drug effects; D018482:Muscle, Skeletal / Q000187:drug effects / Q000503:physiopathology; D009135:Muscular Diseases / Q000276:immunology / Q000503:physiopathology / Q000517:prevention & control*; D010024:Osteoporosis / Q000276:immunology / Q000503:physiopathology / Q000517:prevention & control*; D055070:Resistance Training; D012737:Sex Factors; D014409:Tumor Necrosis Factor-alpha / Q000097:blood; D017962:alpha-Linolenic Acid / Q000008:administration & dosage*
C508600:IL6 protein, human; D018836:Inflammation Mediators; D015850:Interleukin-6; D014409:Tumor Necrosis Factor-alpha; D017962:alpha-Linolenic Acid